Advanced Search

Submit Manuscript



A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant

Zezhong Liu1,† , Jasper Fuk-Woo Chan2,3,4,† , Jie Zhou1,† , Meiyu Wang5,6,† , Qian Wang1 , Guangxu Zhang1 , Wei Xu1 , Kenn Ka-Heng Chik4 , Yilong Zhang7 , Youchun Wang5,6,* , Lu Lu1,* , Kwok-Yung Yuen2,3,4,* , Shibo Jiang1,*

1Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China
2State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China
3Department of Clinical Microbiology and Infection Control, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China
4Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Hong Kong, China
5Graduate School of Peking Union Medical College, Beijing, China
6Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing, China
7Fulgent Pharma LLC., 4978 Santa Anita Avenue, Temple City, CA, USA
These authors contributed equally: Zezhong Liu, Jasper Fuk-Woo Chan, Jie Zhou, Meiyu Wang
* Correspondence: Youchun Wang( Lu( Yuen( Jiang(

Dear Editor,

Since the outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, numerous SARS-CoV-2 variants of concern (VOCs), such as Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), and Delta (B.1.617.2), have emerged. Recently, the newly identified SARS-CoV-2 VOC, Omicron (B.1.1.529), has rapidly spread in many countries1 and is expected to replace Delta as the dominant variant circulating in the world. Compared to other VOCs, Omicron contains at least 32 mutations in spike (S) protein, including 15 mutations in the receptor-binding domain (RBD), and these mutations are known to confer resistance to neutralizing antibodies (nAbs) and sera of convalescent patients and people who have received COVID-19 vaccines.2,3,4,5 Therefore, vaccines able to induce potent and durable neutralizing antibodies against Omicron and other VOCs are urgently needed.


Browse 341